JP2013517299A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517299A5
JP2013517299A5 JP2012549208A JP2012549208A JP2013517299A5 JP 2013517299 A5 JP2013517299 A5 JP 2013517299A5 JP 2012549208 A JP2012549208 A JP 2012549208A JP 2012549208 A JP2012549208 A JP 2012549208A JP 2013517299 A5 JP2013517299 A5 JP 2013517299A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
preparation according
molar ratio
neurostimulatory
steroid anesthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012549208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517299A (ja
JP5930311B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2011/000050 external-priority patent/WO2011088503A1/en
Publication of JP2013517299A publication Critical patent/JP2013517299A/ja
Publication of JP2013517299A5 publication Critical patent/JP2013517299A5/ja
Application granted granted Critical
Publication of JP5930311B2 publication Critical patent/JP5930311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012549208A 2010-01-21 2011-01-19 麻酔薬製剤 Active JP5930311B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (3)

Publication Number Publication Date
JP2013517299A JP2013517299A (ja) 2013-05-16
JP2013517299A5 true JP2013517299A5 (enExample) 2014-03-06
JP5930311B2 JP5930311B2 (ja) 2016-06-08

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549208A Active JP5930311B2 (ja) 2010-01-21 2011-01-19 麻酔薬製剤

Country Status (27)

Country Link
US (2) US8697678B2 (enExample)
EP (1) EP2525798B1 (enExample)
JP (1) JP5930311B2 (enExample)
KR (1) KR101747476B1 (enExample)
CN (1) CN102802635B (enExample)
AU (1) AU2011207103B2 (enExample)
BR (1) BR112012017800B1 (enExample)
CA (1) CA2786762C (enExample)
CL (1) CL2012002032A1 (enExample)
CY (1) CY1119947T1 (enExample)
DK (1) DK2525798T3 (enExample)
ES (1) ES2646829T3 (enExample)
GB (2) GB2491491B (enExample)
HR (1) HRP20171699T1 (enExample)
HU (1) HUE035441T2 (enExample)
LT (1) LT2525798T (enExample)
NO (1) NO2525798T3 (enExample)
NZ (1) NZ601255A (enExample)
PL (1) PL2525798T3 (enExample)
PT (1) PT2525798T (enExample)
RS (1) RS56576B1 (enExample)
RU (1) RU2574022C2 (enExample)
SG (1) SG181997A1 (enExample)
SI (1) SI2525798T1 (enExample)
SM (1) SMT201700518T1 (enExample)
WO (1) WO2011088503A1 (enExample)
ZA (1) ZA201205370B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
JP5819005B2 (ja) * 2011-11-29 2015-11-18 ジュロックス プロプライエタリー リミテッド 薬学的組成物
NZ627781A (en) * 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
SG10201608148TA (en) * 2012-08-21 2016-11-29 Sage Therapeutics Inc Methods Of Treating Epilepsy Or Status Epilepticus
EP2916846B1 (en) * 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
ES2973320T3 (es) 2012-11-30 2024-06-19 Univ California Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016127170A1 (en) * 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017066626A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
TW202400182A (zh) 2016-03-08 2024-01-01 美商賽吉醫療公司 神經活性類固醇,其組合物及用途
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
JP7443358B2 (ja) * 2018-07-03 2024-03-05 ドローブリッジ ファーマシューティカルズ ピーティーワイ リミテッド 神経活性ステロイドおよび調製の方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022514991A (ja) * 2018-12-10 2022-02-16 ハロー・サイエンス・エル・エル・シー 安定な麻酔薬製剤および関連する剤形
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
CN114828889B (zh) 2019-12-06 2025-02-14 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69006259T2 (de) * 1989-05-24 1994-06-09 Innovet Inc Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CA2441744C (en) * 2001-03-20 2011-07-12 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
CN101583620B (zh) * 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法

Similar Documents

Publication Publication Date Title
JP2013517299A5 (enExample)
SI2525798T1 (en) Anesthetic formulation
JP2013018787A5 (enExample)
JP2019131596A5 (enExample)
JP2012526215A5 (enExample)
HRP20120960T1 (hr) Formulacije za lijeäśenje raka
JP2010195825A5 (enExample)
JP2011088913A5 (enExample)
JP2011251975A5 (enExample)
BRPI0920460A2 (pt) eixo de torcao com espessura de parede variavel longitudinalmente
JP2014505733A5 (enExample)
JP2010535814A5 (enExample)
JP2010507451A5 (enExample)
JP2011500690A5 (enExample)
JP2011529948A5 (enExample)
JP2015534578A5 (enExample)
HRP20171175T1 (hr) Novi triciklički spojevi
JP2010270124A5 (enExample)
JP2010522208A5 (enExample)
JP2013517277A5 (enExample)
JP2015531750A5 (enExample)
JP2016147858A5 (enExample)
JP2013529665A5 (enExample)
JP2014097964A5 (enExample)
JP2014530801A5 (enExample)